Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEN1703 +/- Glofitamab in R/R Aggressive B-cell NHL
NCT06534437Phase 2Recruiting
- Sponsor
- Ryvu Therapeutics
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of dapolsertib in B-cell non-Hodgkin lymphoma (3 arms), sponsored by Ryvu Therapeutics. Primary endpoints: Adverse Events at 12 months, Complete Response at 12 months and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
dapolsertib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06534437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534437.